A 12-week, double-blind, multicenter study comparing diflunisal twice daily and ibuprofen four times daily in the treatment of rheumatoid arthritis

Robert (Rob) Bennett

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    Diflunisal, a nonacetylated salicylate preparation with a prolonged duration of action, was compared with ibuprofen for the treatment of rheumatoid arthritis in a multicenter trial comprising 210 patients. Diflunisal was administered twice a day (500 to 750 mg/day) and ibuprofen was administered four times a day (1,600 to 2,400 mg/day). To maintain double-blind conditions, all patients ostensibly followed the same regimen, ingesting their assigned drug and a matching placebo of their nonassigned drug. Disease activity assessments and laboratory tests were done periodically throughout the 12 weeks of the study, and results were compared with pretreatment findings. Efficacy evaluations in 187 patients showed that both treatments were similarly efficacious. Safety and tolerability also were similar in the two groups. Diflunisal, however, offers a more acceptable BID treatment schedule.

    Original languageEnglish (US)
    Pages (from-to)27-36
    Number of pages10
    JournalClinical Therapeutics
    Volume9
    Issue numberSUPPL. C
    StatePublished - 1986

    Fingerprint

    Diflunisal
    Ibuprofen
    Double-Blind Method
    Multicenter Studies
    Rheumatoid Arthritis
    Salicylates
    Pharmaceutical Preparations
    Appointments and Schedules
    Therapeutics
    Placebos
    Safety

    ASJC Scopus subject areas

    • Pharmacology

    Cite this

    A 12-week, double-blind, multicenter study comparing diflunisal twice daily and ibuprofen four times daily in the treatment of rheumatoid arthritis. / Bennett, Robert (Rob).

    In: Clinical Therapeutics, Vol. 9, No. SUPPL. C, 1986, p. 27-36.

    Research output: Contribution to journalArticle

    @article{ac86bb53c1e64c4994bba62596424b86,
    title = "A 12-week, double-blind, multicenter study comparing diflunisal twice daily and ibuprofen four times daily in the treatment of rheumatoid arthritis",
    abstract = "Diflunisal, a nonacetylated salicylate preparation with a prolonged duration of action, was compared with ibuprofen for the treatment of rheumatoid arthritis in a multicenter trial comprising 210 patients. Diflunisal was administered twice a day (500 to 750 mg/day) and ibuprofen was administered four times a day (1,600 to 2,400 mg/day). To maintain double-blind conditions, all patients ostensibly followed the same regimen, ingesting their assigned drug and a matching placebo of their nonassigned drug. Disease activity assessments and laboratory tests were done periodically throughout the 12 weeks of the study, and results were compared with pretreatment findings. Efficacy evaluations in 187 patients showed that both treatments were similarly efficacious. Safety and tolerability also were similar in the two groups. Diflunisal, however, offers a more acceptable BID treatment schedule.",
    author = "Bennett, {Robert (Rob)}",
    year = "1986",
    language = "English (US)",
    volume = "9",
    pages = "27--36",
    journal = "Clinical Therapeutics",
    issn = "0149-2918",
    publisher = "Excerpta Medica",
    number = "SUPPL. C",

    }

    TY - JOUR

    T1 - A 12-week, double-blind, multicenter study comparing diflunisal twice daily and ibuprofen four times daily in the treatment of rheumatoid arthritis

    AU - Bennett, Robert (Rob)

    PY - 1986

    Y1 - 1986

    N2 - Diflunisal, a nonacetylated salicylate preparation with a prolonged duration of action, was compared with ibuprofen for the treatment of rheumatoid arthritis in a multicenter trial comprising 210 patients. Diflunisal was administered twice a day (500 to 750 mg/day) and ibuprofen was administered four times a day (1,600 to 2,400 mg/day). To maintain double-blind conditions, all patients ostensibly followed the same regimen, ingesting their assigned drug and a matching placebo of their nonassigned drug. Disease activity assessments and laboratory tests were done periodically throughout the 12 weeks of the study, and results were compared with pretreatment findings. Efficacy evaluations in 187 patients showed that both treatments were similarly efficacious. Safety and tolerability also were similar in the two groups. Diflunisal, however, offers a more acceptable BID treatment schedule.

    AB - Diflunisal, a nonacetylated salicylate preparation with a prolonged duration of action, was compared with ibuprofen for the treatment of rheumatoid arthritis in a multicenter trial comprising 210 patients. Diflunisal was administered twice a day (500 to 750 mg/day) and ibuprofen was administered four times a day (1,600 to 2,400 mg/day). To maintain double-blind conditions, all patients ostensibly followed the same regimen, ingesting their assigned drug and a matching placebo of their nonassigned drug. Disease activity assessments and laboratory tests were done periodically throughout the 12 weeks of the study, and results were compared with pretreatment findings. Efficacy evaluations in 187 patients showed that both treatments were similarly efficacious. Safety and tolerability also were similar in the two groups. Diflunisal, however, offers a more acceptable BID treatment schedule.

    UR - http://www.scopus.com/inward/record.url?scp=0022921826&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0022921826&partnerID=8YFLogxK

    M3 - Article

    VL - 9

    SP - 27

    EP - 36

    JO - Clinical Therapeutics

    JF - Clinical Therapeutics

    SN - 0149-2918

    IS - SUPPL. C

    ER -